LTR PHARMA LIMITED — Capital/Financing Update 2025

Oct 5, 2025

==> picture [596 x 11] intentionally omitted <==

==> picture [152 x 46] intentionally omitted <==

==> picture [596 x 11] intentionally omitted <==

LTR Pharma increases ownership in LevOmega to ~43% through strategic A$1m investment

6 October 2025

Highlights

• LTR Pharma increases its shareholding in LevOmega Pty Ltd from 33% to ~43% through an A$1m investment.

• Strengthens LevOmega’s development pathway for pharmaceutical-grade, nature-identical omega-3 ingredients.

• Reinforces LTR Pharma’s strategy of building a portfolio of first-in-class solutions addressing large, global unmet needs.

LTR Pharma Limited (ASX:LTP) (“LTR Pharma” or “the Company) is pleased to announce that it has increased its ownership in LevOmega Pty Ltd (“LevOmega”) from 33% to approximately 43%.

This follows LevOmega’s successful completion of a capital raising, which will be used to progress its research and development programs. LTR Pharma’s wholly owned subsidiary, LTR Spectrum Pty Ltd, invested A$1.0 million as part of this raise, resulting in its increased ownership position.

LevOmega was co-founded by LTR Pharma, Levur Pty Ltd and Green Blue Health Pty Ltd, and is focused on the development of sustainable, pharmaceutical-grade omega-3 products. This strategic investment further strengthens LevOmega’s capacity to advance technical validation, pilot production, and commercialisation of its proprietary omega-3 platform.

Global demand for omega-3 oils continues to rise, yet marine sources such as fish oil are increasingly constrained by overfishing, pollution, and declining ocean yields. These pressures are creating quality and sustainability challenges for traditional supply chains. LevOmega’s focus on developing sustainable, pharmaceutical-grade omega-3 products directly addresses these constraints, offering a scalable and reliable alternative.

Omega-3 oil is widely recognised for its cardiovascular and anti-inflammatory health benefits. However, the current reliance on marine harvesting to meet demand is under increasing strain due to overfishing, pollution, and declining yields. Studies note that global nutritional requirements for eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) already exceed sustainable marine supply, and environmental changes continue to affect quality and consistency.

As a result, demand for nature-identical omega-3 products is expected to rise sharply. Traditional fish oil sources are becoming less reliable and consistent due to worsening global ocean conditions, underscoring the need for scalable, sustainable alternatives.

1800 519 711 | ltrpharma.com | investors@ltrpharma.com

LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)

==> picture [596 x 11] intentionally omitted <==

==> picture [152 x 46] intentionally omitted <==

==> picture [596 x 11] intentionally omitted <==

LTR Pharma Executive Chairman, Lee Rodne, said:

“We are delighted to deepen our commitment to LevOmega. This investment not only increases our equity stake to ~43% but also provides LevOmega with the resources to accelerate development of pharmaceutical-grade omega-3 products at a time when traditional fish oil supply chains are under increasing pressure from overfishing, pollution, and declining ocean yields.

For LTR Pharma, this investment underscores our ability to identify and support scalable, first-in-class solutions that address global sustainability challenges while remaining highly complementary to our core intranasal pharmaceutical pipeline.”

- ENDS –

This announcement has been approved by the Board of Directors.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies for significant unmet medical needs through its proprietary intranasal drug delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR’s lead products, SPONTAN[®] and ROXUS[®] , are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing OROFLOW[®] , a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

For further information please contact:

Media enquiries Haley Chartres haley@hck.digital

Investor enquiries Peter McLennan investors@ltrpharma.com

1800 519 711 | ltrpharma.com | investors@ltrpharma.com

LTR Pharma Limited (ABN 64 644 924 569 / ACN 644 924 569)